Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer4 Nov 2026

352 Assessment of the Xiogenix Ares X20+ as an automated fill-finish solution for tumor-infiltrating lymphocyte therapy manufacturing

Chantale Bernatchez¹
Marie-Andree Forget²
Donastas Sakellariou-Thompson¹
Priya Balasubramanian²
Katrina Adlerz²
Jane Zulovich³
Tamara Griffiths⁴
Anindita Ravindran¹
Aemilia Katzinski¹
Lothar Lauterboeck¹

4 affiliations

¹Cell Therapy Manufacturing Center (CTMC), Houston, TX, USA
²Cell Therapy Manufacturing Center, Houston, TX, USA
³1Cell Therapy Manufacturing Center (CTMC), Houston, TX, USA
⁴consultant dermatologist

Open at source DOI Cite

19 Single-cell biophysical profiling as an early predictor of tumor reactivity in tumor-infiltrating lymphocyte manufacturing
Shari Pilon-Thomas, Matthew Beatty, Johannes Ali +9
Journal for ImmunoTherapy of Cancer8 Nov 2026Peer-reviewedCC BYFull textOncologyDOAJ
The Prognostic Role of CD8+ Tumor‐Infiltrating Lymphocyte Density in Head and Neck Mucosal Melanoma
Nicholas K. Fung, Douglas Hartman, Diwakar Davar +1
Otolaryngology--Head and Neck Surgery28 Jul 2026Peer-reviewedLicence not statedFull textOncologyPMC
334 Phase 1 trial of GC101, an IL2free autologous tumor-infiltrating lymphocyte (TIL) therapy, in recurrent high-grade glioma: safety and preliminary efficacy
Qing Lan, Ying Cheng, Yanming Chen +2
Journal for ImmunoTherapy of Cancer6 Nov 2026Peer-reviewedCC BYFull textOncologyDOAJ
A tumor-infiltrating lymphocyte-related prognostic signature for lung adenocarcinoma.
Kang Tian, Xinjie Zhao, Jiajun Du +1
Translational cancer research26 Oct 2026Peer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
Tumour region identification guided scoring (TRIGS) and foundation model-based Tumour Infiltrating Lymphocyte scoring are prognostic for pathological complete response/event free survival in the triple negative patients in the PARTNER randomized controlled trial
P. C. Schouten, M. O. Irfan, Z. Kinsella +15
medRxiv15 Sep 2026PreprintCC BY-NDFull textGeneral medicinemedRxiv

Cite

BibTeX RIS

BibTeX

@article{bernatchez2026assessment,
  title = {{352 Assessment of the Xiogenix Ares X20+ as an automated fill-finish solution for tumor-infiltrating lymphocyte therapy manufacturing}},
  author = {Chantale Bernatchez and Marie-Andree Forget and Donastas Sakellariou-Thompson and Priya Balasubramanian and Katrina Adlerz and Jane Zulovich and Tamara Griffiths and Anindita Ravindran and Aemilia Katzinski and Lothar Lauterboeck},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0352},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0352},
  note = {CC BY},
}

RIS

TY  - JOUR
TI  - 352 Assessment of the Xiogenix Ares X20+ as an automated fill-finish solution for tumor-infiltrating lymphocyte therapy manufacturing
AU  - Chantale Bernatchez
AU  - Marie-Andree Forget
AU  - Donastas Sakellariou-Thompson
AU  - Priya Balasubramanian
AU  - Katrina Adlerz
AU  - Jane Zulovich
AU  - Tamara Griffiths
AU  - Anindita Ravindran
AU  - Aemilia Katzinski
AU  - Lothar Lauterboeck
PY  - 2026
DA  - 2026/11/04
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0352
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0352
SN  - 2051-1426
ER  -

Related

Cite